Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

Published 2017 View Full Article

Authors

Keywords

Epidermal growth factor receptor tyrosine kinase inhibitor, Epidermal growth factor receptor-mutation positive, IPASS study, Non-small-cell lung cancer

Journal

LUNG CANCER

Volume 104, Issue -, Pages 119-125

Publisher

Elsevier BV

Online

2016-12-01

DOI

10.1016/j.lungcan.2016.11.022

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now